Literature DB >> 11464924

Genetic factors in the early diagnosis of ALS.

P M Andersen1.   

Abstract

The frequency of familial amyotrophic lateral sclerosis (ALS) is usually reported as 5-10% of all ALS cases. This figure is probably an underestimate, primarily due to inadequate recording of family history in the patients' charts, and to the not infrequent occurrence of reduced disease penetrance in pedigrees with familial ALS. The true familial ALS frequency may be at least double this. Familial ALS is heterogenetic. The only known ALS-causing gene is the CuZn-superoxide dismutase gene (CuZn-SOD). Mutations in this gene account for a fifth of all familial ALS cases and a few percent of apparent sporadic ALS cases. Genetic testing for CuZn-SOD mutations can help confirm a diagnosis of ALS, especially in cases with atypical features that have been reported in some cases with CuZn-SOD mutations. Genetic testing should only be performed after thorough clinical examination and in cases with a proven or uncertain family history of ALS. It is not warranted in cases with no proven family history for three generations, unless the patient shows the characteristic phenotype associated with recessive inheritance of the D90A CuZn-SOD mutation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11464924     DOI: 10.1080/14660820052415899

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN: 1466-0822


  14 in total

1.  Intermolecular transmission of superoxide dismutase 1 misfolding in living cells.

Authors:  Leslie I Grad; Will C Guest; Anat Yanai; Edward Pokrishevsky; Megan A O'Neill; Ebrima Gibbs; Valentyna Semenchenko; Masoud Yousefi; David S Wishart; Steven S Plotkin; Neil R Cashman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Human cells from cloned embryos in research and therapy.

Authors:  Ian Wilmut
Journal:  BMJ       Date:  2004-02-21

3.  Antecedent Disease is Less Prevalent in Amyotrophic Lateral Sclerosis.

Authors:  Cassie S Mitchell; Sabrina K Hollinger; Shivani D Goswami; Meraida A Polak; Robert H Lee; Jonathan D Glass
Journal:  Neurodegener Dis       Date:  2015-02-20       Impact factor: 2.977

Review 4.  [Amyotrophic lateral sclerosis].

Authors:  R Gastl; A C Ludolph
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

5.  The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man.

Authors:  F J F Broeyer; B E van Aken; J Suzuki; M J B Kemme; H C Schoemaker; A F Cohen; Y Mizushima; J Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

Review 6.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

Review 7.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 8.  4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.

Authors:  Marzia Perluigi; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-15       Impact factor: 8.401

9.  Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes.

Authors:  Shulamit Naor; Zohar Keren; Tomer Bronshtein; Efrat Goren; Marcelle Machluf; Doron Melamed
Journal:  J Neurol       Date:  2009-03-12       Impact factor: 4.849

10.  Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  Luis B Tovar-Y-Romo; Luz Diana Santa-Cruz; Ricardo Tapia
Journal:  Mol Neurodegener       Date:  2009-07-20       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.